Author

K. Modjarrad

Listed by name: these papers carry no ORCID for this author, so different people with the same name may be mixed together.

Biology Disciplines

Click to filter author papers

Immunology· 4 Microbiology· 2 Evolutionary Biology· 1

Signature Assays, Organisms & Methods

Click to filter · or open tag

Approach:experimental assay· 6 Research Focus:host-pathogen & immune response· 5 Research Focus:drug response / drug discovery· 4 Organism:mouse· 3 Organism:human· 2 Assay:proteomics· 2 Research Focus:cell signaling & trafficking· 1 Research Focus:cell type annotation· 1

Frequent Co-Authors

M. G. Joyce· 5 shared N. L. Michael· 3 shared R. S. Sankhala· 3 shared W.-H. Chen· 3 shared A. Anderson· 2 shared A. Hajduczki· 2 shared C. Subra· 2 shared G. R. Matyas· 2 shared

Activity by Year

2020-2023 · peak 3/yr

Co-Author Collaboration Network

10 top collaborators · 40 mutual co-author links

Click any collaborator node to inspect or filter shared papers

Focal author (center)Selected co-authorORCID co-authorUnlinked name

Curved chords = mutual co-authorship

5 shared papersImmunology

M. G. Joyce

Mutual co-authors in cluster

Author profile →

7 papers

Recent·Most cited

Preclinical Characterization of the Omicron XBB.1.5-Adapted BNT162b2 COVID-19 Vaccine

K. Modjarrad, Y. Che, W. Chen, H. Wu, C. I. Cadima, A. Muik, M. S. Maddur, K. R. Tompkins, L. T. Martinez, H. Cai, M. Hong, S. Mensah, B. Cumbia, L. Falcao, J. S. Chang, , K. Swanson

The monovalent Omicron XBB.1.5-adapted BNT162b2 mRNA vaccine elicits stronger neutralizing antibody responses against XBB.1.5 and related sublineages than the bivalent Wild Type + Omicron BA.4/5 vaccine.

bioRxiv · Nov 17, 2023Immunology

A SARS-CoV-2 Spike Ferritin Nanoparticle Vaccine is Protective and Promotes a Strong Immunological Response in the Cynomolgus Macaque Coronavirus Disease 2019 (COVID-19) Model

S. C. Johnston, K. M. Ricks, I. Lakhal-Naouar, A. Jay, C. Subra, J. L. Raymond, H. A. D. King, F. Rossi, T. L. Clements, D. Fetterer, S. Tostenson, C. M. Cincotta, H. R. Hack, C. Kuklis, S. Soman, , A Nalca

This study evaluates a SARS-CoV-2 Spike ferritin nanoparticle vaccine in cynomolgus macaques, showing strong immunological responses and protection against infection.

bioRxiv · Mar 25, 2022Microbiology

Protective Efficacy of Gastrointestinal SARS-CoV-2 Delivery Against Intranasal and Intratracheal SARS-CoV-2 Challenge in Rhesus Macaques

J. Yu, N. Collins, N. B. Mercado, K. McMahan, A. Chandrashekar, J. Liu, T. Anioke, A. Chang, V. Giffin, D. Hope, D. Sellers, F. Nampanya, S. Gardner, J. Barrett, H. Wan, , D. H. Barouch

This study evaluates the protective efficacy of oral SARS-CoV-2 delivery in rhesus macaques against respiratory challenges, finding limited immunogenicity and partial protection.

bioRxiv · Sep 13, 2021Microbiology

SARS-CoV-2 ferritin nanoparticle vaccines elicit broad SARS coronavirus immunogenicity

M. G. Joyce, K. Modjarrad

This paper develops SARS-CoV-2 ferritin nanoparticle vaccines that elicit broad neutralizing antibodies against SARS-CoV-2 and SARS-CoV-1, as well as variants of concern.

bioRxiv · May 9, 2021Immunology

A spike-ferritin nanoparticle vaccine induces robust innate immune activity and drives polyfunctional SARS-CoV-2-specific T cells

J. M. Carmen, S. Shrivastava, Z. Lu, A. Anderson, E. B. Morrison, R. S. Sankhala, W.-H. Chen, W. C. Chang, J. Bolton, G. R. Matyas, N. L. Michael, M. G. Joyce, K. Modjarrad, J. R. Currier, E. Bergmann-Leitner, , M. Rao

This study evaluates a spike-ferritin nanoparticle vaccine with adjuvants, showing enhanced T cell responses and cross-reactivity against SARS-CoV and other coronaviruses.

bioRxiv · Apr 28, 2021 · PreprintImmunology

A SARS-CoV-2 vaccine candidate would likely match all currently circulating strains

B. L. Dearlove, E. Lewitus, H. Bai, Y. Li, D. B. Reeves, M. G. Joyce, P. Scott, M. Amare, S. Vasan, N. L. Michael, K. Modjarrad, M. Rolland

The paper analyzes SARS-CoV-2 sequence diversity and finds limited variation in the Spike protein, suggesting a single vaccine could be effective against current strains.

bioRxiv · Apr 27, 2020Evolutionary Biology

A Cryptic Site of Vulnerability on the Receptor Binding Domain of the SARS-CoV-2 Spike Glycoprotein

M. G. Joyce, R. S. Sankhala, W.-H. Chen, M. Choe, H. Bai, A. Hajduczki, L. Yan, S. L. Sterling, C. Peterson, E. C. Green, C. Smith, N. de Val, M. Amare, P. Scott, E. D. Laing, , K. Modjarrad

The paper reports the high-resolution structure of the SARS-CoV-2 Spike RBD and identifies a conserved epitope accessible in open conformations, which is targeted by cross-reactive antibodies.

bioRxiv · Mar 15, 2020 · PreprintImmunology